ClinicalTrials.govpublic full text
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
multiple myeloma, japan expansion cohort, belantamab mafodotin, relapsed/refractory multiple myeloma, daratumumab, bortezomib, dexamethasone, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 891772
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.